{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:54:29Z","timestamp":1772135669756,"version":"3.50.1"},"reference-count":16,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1248\/bpb.b17-00806","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T22:20:22Z","timestamp":1512512422000},"page":"254-258","source":"Crossref","is-referenced-by-count":19,"title":["Simple Determination of Plasma Ponatinib Concentration Using HPLC"],"prefix":"10.1248","volume":"41","author":[{"given":"Takeo","family":"Yasu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Momo","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Teikyo Heisei University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichirou","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, The Institute of Medical Science, The University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. <i>N. Engl. J. Med.<\/i>, <b>376<\/b>, 629\u2013640 (2017).","DOI":"10.1056\/NEJMoa1612674"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. <i>J. Clin. Oncol.<\/i>, <b>26<\/b>, 127\u2013131 (2008).","DOI":"10.1200\/JCO.2007.13.3223"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jaqiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berqer M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. <i>N. Engl. J. Med.<\/i>, <b>355<\/b>, 2733\u20132743 (2006).","DOI":"10.1056\/NEJMoa064320"},{"key":"4","unstructured":"4) Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipi\u00f1a JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). <i>Blood<\/i>, <b>119<\/b>, 1123\u20131129 (2012)."},{"key":"5","unstructured":"5) Josephs DH, Fisher DS, Spicer J, Flanagan RJ. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. <i>Ther. Drug Monit.<\/i>, <b>35<\/b>, 562\u2013587 (2013)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Herviou P, Thivat E, Richard D, Roche L, Dohou J, Pouget M, Eschalier A, Durando X, Authier N. Therapeutic drug monitoring and tyrosine kinase inhibitors. <i>Oncol Lett.<\/i>, <b>12<\/b>, 1223\u20131232 (2016).","DOI":"10.3892\/ol.2016.4780"},{"key":"7","unstructured":"7) An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCRABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. <i>Leuk. Res.<\/i>, <b>34<\/b>, 1255\u20131268 (2010)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Cortes JE, Kantarjian HM, Br\u00fcmmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leiq E, Gambacorti-Passerini C. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. <i>Blood<\/i>, <b>118<\/b>, 4567\u20134576 (2011).","DOI":"10.1182\/blood-2011-05-355594"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. <i>N. Engl. J. Med.<\/i>, <b>369<\/b>, 1783\u20131796 (2013).","DOI":"10.1056\/NEJMoa1306494"},{"key":"10","unstructured":"10) Otsuka Pharmaceutical Co. Ltd. Iclusig<sup>\u00ae<\/sup> Tablets 15\u2009mg [prescribing information]: \u2039http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/180078_4291048F1020_1_02\u203a, cited 17 October, 2017."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. <i>J. Clin. Pharmacol.<\/i>, <b>53<\/b>, 974\u2013981 (2013).","DOI":"10.1002\/jcph.109"},{"key":"12","unstructured":"12) Kadi AA, Darwish HW, Attwa MW, Amer SM. Validated LC-MS\/MS method for the quantification of ponatinib in plasma: application to metabolic stability. <i>PLOS ONE<\/i>, <b>11<\/b>, e0164967 (2016)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Huynh HH, Pressiat C, Sauvageon H, Madelaine I, Maslanka P, Lebb\u00e9 C, Thieblemont C, Goldwirt L, Mourah S. Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC-MS\/MS. <i>Ther. Drug Monit.<\/i>, <b>39<\/b>, 43\u201354 (2017).","DOI":"10.1097\/FTD.0000000000000357"},{"key":"14","unstructured":"14) US Food and Drug Administration. \u201cGuidance for Industry: Bioanalytical Method Validation (2001)\u201d: \u2039https:\/\/www.fda.gov\/downloads\/Drugs\/Guidance\/ucm070107.pdf\u203a, cited 1 May, 2017."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tuqnati M, Narasimhan NI, Lustqarten S, Farin H, Haluska F, Ohyashiki K. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1\/2 study. <i>Int. J. Hematol.<\/i>, <b>106<\/b>, 385\u2013397 (2017).","DOI":"10.1007\/s12185-017-2238-9"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O\u2019Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. <i>N. Engl. J. Med.<\/i>, <b>367<\/b>, 2075\u20132088 (2012).","DOI":"10.1056\/NEJMoa1205127"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/2\/41_b17-00806\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T13:20:07Z","timestamp":1570454407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/2\/41_b17-00806\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00806","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}